A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Status:
Recruiting
Trial end date:
2024-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability
and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects
with FSGS.